Moloud Akbarzadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Moloud Akbarzadeh has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Ostadrahimi
Nutrition Research Center Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Erfan Banisefid
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Neda Roshanravan
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Ahmad Separham
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication - Ali Farzane
Department of Health Information Management, School of Allied Medical Science, Tehran University of Medical Sciences, Tehran 11369, Iran
1 shared publication - Amir Fattahi
Women’s Reproductive Health Research Center, Tabriz University of medical sciences, Tabriz, Iran
1 shared publication
Latest Publications
- Open Access
- 1 April 2025
- Published by Maad Rayan Publishing Company in Biomedicine Advances
- Vol. 2 (2) , 83-91
Effect of inulin supplementation on MDA level and expression of pyroptosis-related genes in type 2 diabetic patients
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with significant health implications. Probiotic fibers like inulin have shown the potential to improve glucose metabolism by modulating gut microbiota and related signaling pathways. This study focuses on the effect of inulin on malondialdehyde (MDA) level and expression of pyroptosis-related genes (TLR4, ASC, NLRP3, and caspase-1) in type 2 diabetic patients. Methods: In the current clinical trial, 46 patients with T2DM were randomly allocated into inulin (n=23) or placebo (n=23) group for eight weeks. Pyroptosis-related genes expression analysis was performed using real-time polymerase chain reaction (PCR). Findings: Inulin supplementation significantly reduced weight, body mass index (BMI), and waist/hip circumferences. However, no significant changes were observed in Pyroptosis-related genes expression (TLR4, ASC, NLRP3, caspase-1) or MDA serum levels. Baseline differences in dietary intake were adjusted during the analysis. Conclusion: Inulin supplementation is linked to reductions in body weight, BMI, waist and hip circumference. However, no significant association was observed with serum MDA levels or the expression of TLR4, ASC, NLRP3, and caspase-1 genes. Trial Registration: Identifier: IRCT201605262017N29; https://irct.behdasht.gov.ir/.
- 1 April 2025
- Published by Maad Rayan Publishing Company in Biomedicine Advances
- Vol. 2 (2) , 83-91
Open AccessEffect of inulin supplementation on MDA level and expression of pyroptosis-related genes in type 2 diabetic patients
Introduction: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with significant health implications. Probiotic fibers like inulin have shown the potential to improve glucose metabolism by modulating gut microbiota and related signaling pathways. This study focuses on the effect of inulin on malondialdehyde (MDA) level and expression of pyroptosis-related genes (TLR4, ASC, NLRP3, and caspase-1) in type 2 diabetic patients. Methods: In the current clinical trial, 46 patients with T2DM were randomly allocated into inulin (n=23) or placebo (n=23) group for eight weeks. Pyroptosis-related genes expression analysis was performed using real-time polymerase chain reaction (PCR). Findings: Inulin supplementation significantly reduced weight, body mass index (BMI), and waist/hip circumferences. However, no significant changes were observed in Pyroptosis-related genes expression (TLR4, ASC, NLRP3, caspase-1) or MDA serum levels. Baseline differences in dietary intake were adjusted during the analysis. Conclusion: Inulin supplementation is linked to reductions in body weight, BMI, waist and hip circumference. However, no significant association was observed with serum MDA levels or the expression of TLR4, ASC, NLRP3, and caspase-1 genes. Trial Registration: Identifier: IRCT201605262017N29; https://irct.behdasht.gov.ir/.
- 27 July 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (9) , 7527-7533
The expression levels of PPAR-α/γ and UCP1/2 on the slow coronary flow phenomenon; results from a case–control study
Purpose The slow coronary flow (SCF) phenomenon is considered a coronary artery disorder. Because of the critical function of peroxisome proliferator-activated receptors (PPARs) in regulating the oxidative stress and inflammatory reactions in cardiovascular disease, The aim of the current study was to investigate the expression of the genes for uncoupling proteins 1 and 2 (UCP1 and UCP2), peroxisome proliferator-activated receptors and (PPAR- PPAR-), and PPAR- in SCF patients. Methods In this case–control study, coronary angiography examination was used to analyze 35 individuals with SCF and 35 subjects with normal coronary flow (NCF). SCF was diagnosed using the TIMI (thrombolysis in myocardial infarction frame count) method. The SCF phenomenon is thought to be the TIMI > 27. In the peripheral blood mononuclear cells (PBMCs), the messenger ribonucleic acid (mRNA) expression levels of the PPAR-, PPAR-, UCP1, and UCP2 genes were evaluated. Results UCP1 and UCP2 expression levels were significantly higher in the SCF group compared to the NCF group (P = 0.034 and P0.001, respectively). The PPAR- and PPAR- levels were found to be significantly lower in the SCF group compared to the NCF group (P = 0.015, P0.001, respectively). According to the results of the logistic regression analysis, high UCP1 and UCP2 levels and low PPAR- and PPAR- levels are each independent predictors of the SCF phenomenon. Conclusion This research provided evidence about the potential role of PPAR-α, PPAR-γ, UCP1, and UCP2 as biomarkers in SCF. More investigations are suggested to assess the functions of these factors in SCF patients mechanistically.
- 27 July 2023
- Published by Springer Nature in Molecular Biology Reports
- Vol. 50 (9) , 7527-7533
The expression levels of PPAR-α/γ and UCP1/2 on the slow coronary flow phenomenon; results from a case–control study
Purpose The slow coronary flow (SCF) phenomenon is considered a coronary artery disorder. Because of the critical function of peroxisome proliferator-activated receptors (PPARs) in regulating the oxidative stress and inflammatory reactions in cardiovascular disease, The aim of the current study was to investigate the expression of the genes for uncoupling proteins 1 and 2 (UCP1 and UCP2), peroxisome proliferator-activated receptors and (PPAR- PPAR-), and PPAR- in SCF patients. Methods In this case–control study, coronary angiography examination was used to analyze 35 individuals with SCF and 35 subjects with normal coronary flow (NCF). SCF was diagnosed using the TIMI (thrombolysis in myocardial infarction frame count) method. The SCF phenomenon is thought to be the TIMI > 27. In the peripheral blood mononuclear cells (PBMCs), the messenger ribonucleic acid (mRNA) expression levels of the PPAR-, PPAR-, UCP1, and UCP2 genes were evaluated. Results UCP1 and UCP2 expression levels were significantly higher in the SCF group compared to the NCF group (P = 0.034 and P0.001, respectively). The PPAR- and PPAR- levels were found to be significantly lower in the SCF group compared to the NCF group (P = 0.015, P0.001, respectively). According to the results of the logistic regression analysis, high UCP1 and UCP2 levels and low PPAR- and PPAR- levels are each independent predictors of the SCF phenomenon. Conclusion This research provided evidence about the potential role of PPAR-α, PPAR-γ, UCP1, and UCP2 as biomarkers in SCF. More investigations are suggested to assess the functions of these factors in SCF patients mechanistically.
- Open Access
- 8 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10874
Melatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved
Hypoxia has an important role in tumor progression via the up-regulation of growth factors and cellular adaptation genes. These changes promote cell survival, proliferation, invasion, metastasis, angiogenesis, and energy metabolism in favor of cancer development. Hypoxia also plays a central role in determining the resistance of tumors to chemotherapy. Hypoxia of the tumor microenvironment provides an opportunity to develop new therapeutic strategies that may selectively induce apoptosis of the hypoxic cancer cells. Melatonin is well known for its role in the regulation of circadian rhythms and seasonal reproduction. Numerous studies have also documented the anti-cancer properties of melatonin, including anti-proliferation, anti-angiogenesis, and apoptosis promotion. In this paper, we hypothesized that melatonin exerts anti-cancer effects by inhibiting hypoxia-induced pathways. Considering this action, co-administration of melatonin in combination with other therapeutic medications might increase the effectiveness of anti-cancer drugs. In this review, we discussed the possible signaling pathways by which melatonin inhibits hypoxia-induced cancer cell survival, invasion, migration, and metabolism, as well as tumor angiogenesis.
- 8 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (19) , 10874
Open AccessMelatonin as a Therapeutic Agent for the Inhibition of Hypoxia-Induced Tumor Progression: A Description of Possible Mechanisms Involved
Hypoxia has an important role in tumor progression via the up-regulation of growth factors and cellular adaptation genes. These changes promote cell survival, proliferation, invasion, metastasis, angiogenesis, and energy metabolism in favor of cancer development. Hypoxia also plays a central role in determining the resistance of tumors to chemotherapy. Hypoxia of the tumor microenvironment provides an opportunity to develop new therapeutic strategies that may selectively induce apoptosis of the hypoxic cancer cells. Melatonin is well known for its role in the regulation of circadian rhythms and seasonal reproduction. Numerous studies have also documented the anti-cancer properties of melatonin, including anti-proliferation, anti-angiogenesis, and apoptosis promotion. In this paper, we hypothesized that melatonin exerts anti-cancer effects by inhibiting hypoxia-induced pathways. Considering this action, co-administration of melatonin in combination with other therapeutic medications might increase the effectiveness of anti-cancer drugs. In this review, we discussed the possible signaling pathways by which melatonin inhibits hypoxia-induced cancer cell survival, invasion, migration, and metabolism, as well as tumor angiogenesis.